Analisis Efektifitas Biaya Terapi Pengobatan Pasien Diabetes Mellitus Tipe 2 terhadap Kontrol Glukosa Darah

Ninik Mas Ulfa; Selly Septi Fandinata; Indra Puspitasari

doi:10.22435/jki.v13i1.6170

Ninik Mas Ulfa Akademi Farmasi Surabaya, Surabaya, Indonesia
Selly Septi Fandinata Akademi Farmasi Surabaya, Surabaya, Indonesia
Indra Puspitasari Akademi Farmasi Surabaya, Surabaya, Indonesia

DOI: https://doi.org/10.22435/jki.v13i1.6170

Keywords: Cost effectiveness analysis, Type 2 diabetes mellitus, Blood glucose, Outpatient

Abstract

Diabetes mellitus (DM) is a chronic disease characterized by blood glucose levels exceeding normal. The length of therapy in DM patients causes the large amount of treatment costs incurred, although in Indonesia BPJS insurance is used but this puts the burden of health financing on the Indonesian government, so there is a need for an analysis of costs associated with therapeutic outcomes. The purpose of this study was to analyze the Cost Effectiveness of Type 2 DM patients in a hospital in the South Surabaya area. The method used is observation, with retrospective observation on type 2 DM patients in outpatient internal polyclinics for the period April – December 2021. The results obtained were 30 patients who routinely controlled 2, 3, 4, 5, 6, 7, 8 and 9 months, receiving single therapy or a combination of antidiabetic drugs. In this study, a cost and effectiveness analysis was carried out with the measurement of therapeutic outcomes, namely pre-post GDP and pre-post GD2PP. The conclusion of this study were 30 female patients (100%), age > 45 years 24 people (80%). The effectiveness of sulfonylurea single therapy is 50% with an ACER of between Rp. 4,392.48 – Rp. 18,686.86 routine control 2, 3 and 9 months. For the treatment of 2 combinations of Thiazolidinediones + Insulin has an effectiveness value of 100% with ACER Rp. 42,490.08 routine control 6 months. While the 3 combinations that have a 100% effectiveness value are the combination of Sulfonylurea + Thiazolidinedione + Biguanide with an ACER price of Rp. 6,668.4 routine follow-up for 3 months. In 3 combinations of oral antidiabetic with insulin (Insulin + Sulfonylurea + Thiazolidioine + alpha glucosidase inhibitor) has a 100% effectiveness value, the ACER price is Rp. 36,082.36 routine control 7 months.

References

Indonesia KKR. Infodatin-2020-Diabetes-Melitus.pdf. In.

Dinkes Kota Surabaya. Profil Kesehatan Kota Surabaya 2019. Vol. 4, Buku. 2557. 88–100 p.

Maharrani A. BPJS Kesehatan keluar Rp6,1 triliun untuk tangani diabetes [Internet]. [cited 2023 Jan 10]. Available from: https://www.manajemen-pembiayaankesehatan.net/index.php/berita-nasional/2787-bpjs-kesehatan-keluar-rp6-1-triliun-untuk-tangani-diabetes

Kemenkes RI. Hasil Riset Kesehatan Dasar Tahun 2018. Kementrian Kesehat RI. 2018;53(9):1689–99.

Soelistijo S, Lindarto D, Decroli E, Permana H, Sucipto K, Kusnadi Y et al. Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia. Perkeni. 2019. 133 p.

GINA. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2015. (2015). PB PERKENI. Glob Initiat Asthma [Internet]. 2020;46. Available from: www.ginasthma.org.

Priyadi A, Permana H, Muhtadi A, Sumiwi SA, Sinuraya RK, Suwantika AA. Cost-effectiveness analysis of type 2 diabetes mellitus (T2dm) treatment in patients with complications of kidney and peripheral vascular diseases in Indonesia. Healthc. 2021;9(2):1–9.

Banerji MA, Dunn JD. Impact of glycemic control on healthcare resource utilization and costs of type 2 diabetes: Current and future pharmacologic approaches to improving outcomes. Am Heal Drug Benefits. 2013;6(7):382–92.

Yuswantina R, Dyahariesti N. Analisis Efektivitas Biaya Penggunaan Antidiabetes Oral Tunggal dan Kombinasi Pada Pasien BPJS Penderita Diabetes Melitus Tipe 2 di Rumah Sakit X. Media Farm Indones [Internet]. 2018;13(1):1340–6. Available from: https://stifar.ac.id/ojs/index.php/MFI/article/view/47

Gonçalves ACO, Cazarim MDS, Sanches C, Pereira LRL, Camargos AMT, Aquino JA, et al. Cost-effectiveness analysis of a pharmacotherapeutic empowerment strategy for patients with type 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2019;7(1).

Baroroh F, Solikah WY, Urfiyya QA. Analisis Biaya Terapi Diabetes Melitus Tipe 2 di Rumah Sakit PKU Muhammadiyah Bantul Yogyakarta. J Farm Sains dan Prakt [Internet]. 2016;I(2):11–22. Available from: https://journal.unimma.ac.id/index.php/pharmacy/article/download/230/168/

Gray A, Turner R, Raikou M, McGuire A, Fenn P, Stevens R, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: Economic analysis alongside randomised controlled trial (UKPDS 41). Br Med J. 2000;320(7246):1373–8.

Mounié M, Costa N, Gourdy P, Latorre C, Schirr-Bonnans S, Lagarrigue JM, et al. Cost-Effectiveness Evaluation of a Remote Monitoring Programme Including Lifestyle Education Software in Type 2 Diabetes: Results of the Educ@dom Study. Diabetes Ther. 2022;13(4):693–708.

Lilyawati SA, Fitriani N, Prasetya F. Proceeding of Mulawarman Pharmaceuticals Conferences. Proceeding Mulawarman Pharm Conf [Internet]. 2019;(April 2021):135–8. Available from: http://prosiding.farmasi.unmul.ac.id/index.php/mpc/article/view/416/399

Achmad A. Kejadian Efek Samping Potensial Terapi Obat Anti Diabetes Pada Pasien Diabetes Melitus Berdasarkan Algoritme Naranjo. Pharm J Indones. 2017;2(2):45–50.

Diabetes N, Initiative E. 2015 American Diabetes Association ( ADA ) Diabetes Guidelines Summary Recommendations from NDEI 1 . Diabetes Diagnosis. 2015;

Isnani N, Muliyani M, Zaini M, Arif Riyadi M. Analisis Efektivitas Biaya (Cost-Effectiveness) Penggunaan Antidiabetes Oral Kombinasi Pada Pasien Diabetes Melitus Tipe II Rawat Jalan Di Rsud Dr. H. Moch. Ansari Saleh Banjarmasin. J Insa Farm Indones. 2021;4(1):103–10.

Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, et al. Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Front Endocrinol (Lausanne). 2017;8(January).

Laelasari E, Sauriasari R, Banun A. Cost-effectiveness analysis of insulin, sulfonylurea, and sulfonylurea– Metformin in type 2 diabetes mellitus. Asian J Pharm Clin Res. 2017;10(Special Issue October):50–3.